BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34243220)

  • 1. Transition of cutaneous into systemic lupus erythematosus following adenoviral vector-based SARS-CoV-2 vaccination.
    Kreuter A; Burmann SN; Burkert B; Oellig F; Michalowitz AL
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e733-e735. PubMed ID: 34243220
    [No Abstract]   [Full Text] [Related]  

  • 2. Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine.
    Joseph AK; Chong BF
    Dermatol Ther; 2021 Nov; 34(6):e15114. PubMed ID: 34455671
    [No Abstract]   [Full Text] [Related]  

  • 3. Subacute cutaneous lupus erythematosus induction after SARS-CoV-2 vaccine in a patient with primary biliary cholangitis.
    Zengarini C; Pileri A; Salamone FP; Piraccini BM; Vitale G; La Placa M
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):e179-e180. PubMed ID: 34807495
    [No Abstract]   [Full Text] [Related]  

  • 4. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis.
    Hinterseher J; Hertl M; Didona D
    J Dtsch Dermatol Ges; 2023 Aug; 21(8):853-861. PubMed ID: 37218538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New-onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination.
    Zavala-Miranda MF; González-Ibarra SG; Pérez-Arias AA; Uribe-Uribe NO; Mejia-Vilet JM
    Kidney Int; 2021 Dec; 100(6):1340-1341. PubMed ID: 34560139
    [No Abstract]   [Full Text] [Related]  

  • 6. Systemic lupus erythematosus after COVID-19 vaccination: A case report.
    Patil S; Patil A
    J Cosmet Dermatol; 2021 Oct; 20(10):3103-3104. PubMed ID: 34418261
    [No Abstract]   [Full Text] [Related]  

  • 7. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
    Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A
    Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
    Barbhaiya M; Levine JM; Siegel CH; Bykerk VP; Jannat-Khah D; Mandl LA
    Clin Rheumatol; 2022 May; 41(5):1619-1622. PubMed ID: 34716843
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter to the editor regarding the article ''Patil S, Patil A. Systemic lupus erythematosus after COVID-19 vaccination: A case report. J Cosmet Dermatol. 2021 Aug 21. 10.1111/jocd.14386".
    Abdullah L; Awada B; Kurban M; Abbas O
    J Cosmet Dermatol; 2021 Dec; 20(12):4076-4077. PubMed ID: 34699662
    [No Abstract]   [Full Text] [Related]  

  • 10. SARS-CoV-2 vaccination efficacy and B-cell depletion therapy in systemic lupus erythematosus: Description of a case.
    Ceccarelli F; Olivieri G; Natalucci F; Alessandri C; Conti F
    Lupus; 2021 Sep; 30(10):1698-1699. PubMed ID: 34192958
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic Lupus Erythematosus and COVID-19.
    Pappa M; Panagiotopoulos A; Thomas K; Fanouriakis A
    Curr Rheumatol Rep; 2023 Oct; 25(10):192-203. PubMed ID: 37477841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ocular adverse event in temporal association with COVID-19 vaccination in a patient with systemic lupus erythematosus: a case report.
    Jin W; Tang Y; Wen C
    Hum Vaccin Immunother; 2021 Nov; 17(11):4102-4104. PubMed ID: 34617875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.
    Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Kittanamongkolchai W
    RMD Open; 2021 Dec; 7(3):. PubMed ID: 34862313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
    Zavala-Flores E; Salcedo-Matienzo J; Quiroz-Alva A; Berrocal-Kasay A
    Clin Rheumatol; 2022 May; 41(5):1349-1357. PubMed ID: 34782941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of COVID-19 Vaccines in Patients with SLE.
    Tang W; Gartshteyn Y; Ricker E; Inzerillo S; Murray S; Khalili L; Askanase A
    Curr Rheumatol Rep; 2021 Nov; 23(11):79. PubMed ID: 34767100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lupus, vaccinations and COVID-19: What we know now.
    Mason A; Anver H; Lwin M; Holroyd C; Faust SN; Edwards CJ
    Lupus; 2021 Sep; 30(10):1541-1552. PubMed ID: 34134555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exacerbation of Chronic Cutaneous Lupus Erythematosus Triggered by Vaccine Against COVID-19.
    Souza EN; Diniz LM; Moura LAD; Oliosi AC
    Actas Dermosifiliogr; 2024 Apr; 115(4):T430-T432. PubMed ID: 38325543
    [No Abstract]   [Full Text] [Related]  

  • 18. Exacerbation of Chronic Cutaneous Lupus Erythematosus Triggered by Vaccine Against COVID-19.
    Souza EN; Diniz LM; Moura LAD; Oliosi AC
    Actas Dermosifiliogr; 2024 Apr; 115(4):430-432. PubMed ID: 36511288
    [No Abstract]   [Full Text] [Related]  

  • 19. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis.
    Bartels LE; Ammitzbøll C; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Thomsen MK; Erikstrup C; Hauge EM; Troldborg A
    Rheumatol Int; 2021 Nov; 41(11):1925-1931. PubMed ID: 34476603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE).
    Mageau A; Ferré VM; Goulenok T; Charpentier C; Delory N; Francois C; Houhou-Fidouh N; Papo T; Descamps D; Sacre K
    Ann Rheum Dis; 2022 Aug; 81(8):1194-1196. PubMed ID: 35396228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.